LEGN LEGN
Company Profile ↓Company Overview
LEGN (LEGN) is a publicly traded company listed on with a market capitalization of $7.05B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 106.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $1.03B (+64.0% YoY); net profit $-296.80M.
- Trailing 12 Months Year-on-year growth — revenue +64.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 106.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 106.41% |
| 1 Year: | 64.02% |
Stock Price Performance
| 1 Year: | -50.46% |
| 6 Months: | +14.35% |
| 3 Months: | -33.18% |
| 1 Month: | -31.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)27.56 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 106.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 50.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 195.00M | 255.06M | 272.33M | 306.38M | 305.10M |
| Cost of Revenue | - | 71.30M | 97.99M | 115.31M | 123.46M | 175.90M |
| Gross Profit | - | 123.70M | 157.07M | 157.02M | 182.92M | 129.20M |
| Operating Expenses | - | 175.40M | 178.95M | 200.48M | 203.52M | 179.00M |
| Operating Income | - | -51.70M | -21.88M | -43.45M | -20.60M | -49.80M |
| EBITDA | - | -89.00M | -113.62M | -27.56M | -2.15M | -32.00M |
| Interest Expense | - | 5.10M | 5.22M | 5.64M | 5.48M | 5.50M |
| Pretax Income | - | -99.20M | -124.80M | -39.07M | -19.60M | -53.10M |
| Tax Provision | - | 1.80M | 582.00K | 616.00K | 11.22M | 1.20M |
| Net Income | - | -101.00M | -125.38M | -39.69M | -30.82M | -54.30M |
| Diluted EPS | - | -0.54 | -0.68 | -0.22 | -0.16 | -0.30 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 117.00M | 285.10M | 627.30M | 1.03B |
| Cost of Revenue | 65.36M | 144.20M | 234.60M | 408.10M |
| Gross Profit | 51.64M | 140.90M | 392.70M | 620.80M |
| Operating Expenses | 507.26M | 669.00M | 702.20M | 757.30M |
| Operating Income | -455.62M | -528.10M | -309.50M | -136.50M |
| EBITDA | -416.54M | -479.90M | -115.10M | -232.30M |
| Interest Expense | 10.80M | 21.80M | 21.60M | 21.40M |
| Pretax Income | -445.72M | -520.20M | -158.10M | -282.60M |
| Tax Provision | 625.00K | -1.90M | 18.90M | 14.20M |
| Net Income | -446.35M | -518.30M | -177.00M | -296.80M |
| Diluted EPS | -2.80 | -2.94 | -0.96 | -1.62 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.33B | 1.85B | 1.67B | 1.73B |
| Current Assets | - | 1.10B | 1.50B | 1.28B | 1.25B |
| Cash & Equivalents | - | 786.03M | 1.28B | 286.70M | 901.90M |
| Inventory | - | 10.35M | 19.43M | 23.90M | 32.00M |
| Receivables | - | 90.00K | 100.04M | 6.40M | 13.10M |
| Total Liabilities | - | 586.65M | 597.24M | 629.60M | 731.60M |
| Current Liabilities | - | 297.79M | 216.42M | 277.70M | 636.40M |
| Long Term Debt | 120.46M | 260.93M | 281.33M | 301.20M | - |
| Total Debt | - | 284.53M | 328.67M | 350.60M | 413.70M |
| Total Equity | - | 744.31M | 1.25B | 1.04B | 1.00B |
| Shares Outstanding | - | 330.13M | 363.82M | 367.30M | 369.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -201.28M | -393.30M | -144.00M | -100.20M |
| Investing Cash Flow | - | -77.09M | 92.90M | -850.60M | 709.60M |
| Financing Cash Flow | - | 377.98M | 791.40M | 5.70M | -300.00K |
| Capital Expenditure | - | -22.27M | -22.70M | -14.10M | -28.60M |
| Free Cash Flow | - | -223.56M | -416.00M | -158.10M | -128.80M |
| Net Change in Cash | - | 99.60M | 491.00M | -988.90M | 609.10M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 44.1% | 49.4% | 62.6% | 60.3% |
| Operating Margin % | -389.4% | -185.2% | -49.3% | -13.3% |
| Net Margin % | -381.5% | -181.8% | -28.2% | -28.8% |
| ROE % | -60.0% | -41.4% | -17.0% | -29.6% |
| ROCE % | -44.1% | -32.4% | -22.2% | -12.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LEGN
Legend Biotech (LEGN) Stock May Be Cheap After CEO Resignation
Legend Biotech stock has seen a steep share price decline over the past few years, yet the latest valuation checks still point to shares screening as cheap on several measures. With fresh leadership changes and ongoing focus on its key CAR-…
Legend Biotech (LEGN) CEO Exit Tests Management Stability Around Its CAR-T Multiple Myeloma Strategy
Legend Biotech recently announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and Board member, effective July 24, 2026, with CARVYKTI business unit President Alan Bash appointed as Interim CEO and Dr. Huang staying …
Legend Biotech (LEGN) Replaces CEO Ying Huang With Interim Chief Alan Bash
Legend Biotech, listed as NasdaqGS:LEGN, announced that CEO Ying Huang has stepped down. Alan Bash has been appointed as Interim CEO to lead the company through the transition. The leadership change comes at a time when Legend Biotech remai…
Leadership changes afoot at two CGT biotechs
Legend Biotech’s CEO stepped down without warning, while Sarepta has appointed a biopharma veteran to take the company forward.
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
BRIDGEWATER N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, August 11, 2026, to revie…
LEGN Stock Plunges 15% After Sudden CEO Exit — But Analyst Reiterates Optimism In Company’s Under-Development Lymphoma Asset
Legend said on Monday that Ying Huang stepped down as chief executive officer and board member effective July 24.
LEGN — Frequently Asked Questions
What is the current share price of LEGN?
As of 2026-08-05 17:25 PDT, LEGN trades at $19.05 on NASDAQ/NYSE. Its 52-week range is $16.65 to $38.45.
What is the market capitalisation of LEGN?
LEGN has a market capitalisation of $7.05B on NASDAQ/NYSE.
What is the P/E ratio of LEGN?
LEGN trades at a trailing price-to-earnings (P/E) ratio of -11.76. Its price-to-book (P/B) ratio is 7.03.
What is the return on equity (ROE) of LEGN?
LEGN has a return on equity (ROE) of -29.62%. Its return on capital employed (ROCE) is -12.44%.
Is LEGN a good stock to buy?
This page provides a data-driven analysis of LEGN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.